New approaches in Sjögren's syndrome therapy

Authors: Ramos-Casals, Manuel; Brito-Zerón, Pilar

Source: Expert Review of Clinical Immunology, Volume 3, Number 2, March 2007 , pp. 195-204(10)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

At present, there is no treatment capable of modifying the evolution of Sjögren's syndrome (SS) and the therapeutic approach is based mainly on symptomatic replacement or stimulation of glandular secretions, while extraglandular involvement requires an organ-specific therapy. New therapeutic approaches for sicca manifestations include oral muscarinic agonists (e.g., pilocarpine and cevimeline) for dry mouth, as well as topical agents (e.g., cyclosporine A and diquafosol) for dry eye. Turning to biological agents, recent studies have demonstrated the lack of efficacy of anti-tumor necrosis factor (TNF) agents in primary SS. By contrast, a promising treatment is rituximab (anti-CD20). Advances in our knowledge of etiopathogenic mechanisms will allow the development of future treatments for SS, including localized gene transfer and agents antagonizing B cell-activating factor from the TNF family and CD22-positive cells.

Keywords: belimumab; cevimeline; epratuzumab; pilocarpine; rituximab; Sjögren's syndrome

Document Type: Research article

DOI: http://dx.doi.org/10.1586/1744666X.3.2.195

Publication date: 2007-03-01

More about this publication?

Expert Review of Clinical Immunology provides expert analysis and commentary regarding the performance of new therapeutic and diagnostic modalities in disease states with a strong immunologic component, such as allergic asthma, rheumatoid arthritis, inflammatory bowel disease, psoriasis and multiple sclerosis
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites